收稿日期: 2019-04-10
网络出版日期: 2019-06-24
基金资助
国家重点研发计划资助项目(2018YFC1312700);国家重点研发计划资助项目(2018YFC1312701);国家自然科学基金资助项目(81625001)
Research Progress on ischemic heart disease and energy metabolism
Received date: 2019-04-10
Online published: 2019-06-24
缺血性心肌病伴随着心脏能量代谢的变化,这些变化主要为脂肪酸氧化速率增加和（或）葡萄糖氧化途径中糖酵解减少。通过减少脂肪酸氧化或者增加葡萄糖氧化的方式干预能量代谢,能够改善缺血性心肌病的病理变化和心脏功能。随着代谢组学检测技术的发展,针对缺血性心肌病进行早期代谢产物检测手段和机制探索方式更加多样,丰富了目前对缺血性心肌病代谢变化的认知。同时,了解并分析缺血性心肌病的代谢变化为缺血性心肌病的创新药物研发提供新线索。本文系统介绍了缺血性心脏病中三大营养物质能量代谢变化,干预不同能量变化在心脏功能障碍中的作用,并探讨通过代谢手段治疗缺血性心脏疾病的可能性。
张剑姝, 徐明 . 缺血性心肌病与能量代谢研究进展[J]. 上海大学学报(自然科学版), 2019 , 25(3) : 357 -364 . DOI: 10.12066/j.issn.1007-2861.2135
Ischemia heart disease is often accompanied by cardiac energy metabolism, which is reflected in contractile dysfunction and a decrease in cardiac efficiency. Specific metabolic changes include a relative increase in cardiac fatty acid oxidation rates and an uncoupling of glycolysis from glucose oxidation. Recent evidence suggests that therapeutically regulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation can improve cardiac function of the ischemic heart. With the development of metabolomics technology, the detection methods and mechanisms of early metabolites for ischemic cardiomyopathy are further explored. This paper first discusses systematically the change of energy metabolic which contributes to cardiac dysfunction, and then it explores the potential for targeting treatment ischemic heart disease through metabolic pathway.
| [1] | Fillmore N, Levasseur J L, Fukushima A , et al. Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction[J]. Mol Med, 2018,24(1):3. |
| [2] | Fillmore N, Mori J, Lopaschuk G D . Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy[J]. Br J Pharmacol, 2014,171(8):2080-2090. |
| [3] | Stanley W C, Recchia F A, Lopaschuk G D . Myocardial substrate metabolism in the normal and failing heart. Physiol Rev, 2005,85(3):1093-1129. |
| [4] | McGarrah R W, Crown S B, Zhang G F , et al. Cardiovascular metabolomics[J]. Circ Res, 2018,122(9):1238-1258. |
| [5] | Lopaschuk G D, Ussher J R, Folmes C D , et al. Myocardial fatty acid metabolism in health and disease[J]. Physiol Rev, 2010,90(1):207-258. |
| [6] | Chouchani E T, Pell V R, Gaude E , et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS[J]. Nature, 2014,515(7527):431-435. |
| [7] | Yue T L, Bao W, Jucker B M , et al. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury[J]. Circulation, 2003,108(19):2393-2399. |
| [8] | Liu Z, Chen J M, Huang H , et al. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway[J]. Metabolism, 2016,65(3):122-130. |
| [9] | Killalea S M, Krum H . Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease[J]. Am J Cardiovasc Drugs, 2001,1(3):193-204. |
| [10] | Dyck J R, Cheng J F, Stanley W C , et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation[J]. Circ Res, 2004,94(9):e78-e84. |
| [11] | Sun W, Liu Q, Leng J , et al. The role of Pyruvate Dehydrogenase Complex in cardiovascular diseases[J]. Life Sci, 2015,121:97-103. |
| [12] | Li X, Liu J, Hu H , et al. Dichloroacetate ameliorates cardiac dysfunction caused by ischemic insults through AMPK signal pathway-not only shifts metabolism[J]. Toxicol Sci, 2019,167(2):604-617. |
| [13] | Ussher J R, Wang W, Gandhi M , et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury[J]. Cardiovasc Res, 2012,94(2):359-369. |
| [14] | Folmes C D, Sowah D, Clanachan A S , et al. High rates of residual fatty acid oxidation during mild ischemia decrease cardiac work and efficiency[J]. J Mol Cell Cardiol, 2009,47(1):142-148. |
| [15] | Hooper L, Martin N, Abdelhamid A , et al. Reduction in saturated fat intake for cardiovascular disease[J]. Cochrane Database Syst Rev, 2015 (6): CD011737. |
| [16] | Wang D D, Li Y, Chiuve S E , et al. Association of specific dietary fats with total and cause-specific mortality[J]. JAMA Intern Med, 2016,176(8):1134-1145. |
| [17] | Gonzalez-Rodriguez A, Mayoral R, Agra N , et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD[J]. Cell Death Dis, 2014,5:e1179. |
| [18] | van de Weijer T, Schrauwen-Hinderling V B, Schrauwen P . Lipotoxicity in type 2 diabetic cardiomyopathy[J]. Cardiovasc Res, 2011,92(1):10-18. |
| [19] | Holland W L, Summers S A . Strong heart, low ceramides[J]. Diabetes, 2018,67(8):1457-1460. |
| [20] | Laaksonen R, Ekroos K, Sysi-Aho M , et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J, 2016,37(25):1967-1976. |
| [21] | Souza-Mello V . Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease[J]. World J Hepatol, 2015,7(8):1012-1019. |
| [22] | Dezsi C A . Trimetazidine in practice: review of the clinical and experimental evidence[J]. Am J Ther, 2016,23(3):e871-e879. |
| [23] | Danchin N, Marzilli M, Parkhomenko A , et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis[J]. Cardiology, 2011,120(2):59-72. |
| [24] | Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina [J]. Cochrane Database Syst Rev, 2005 (4): CD003614. |
| [25] | Zhao Q, Cui Z, Zheng Y , et al. Fenofibrate protects against acute myocardial I/R injury in rat by suppressing mitochondrial apoptosis as decreasing cleaved caspase-9 activation[J]. Cancer Biomark, 2017,19(4):455-463. |
| [26] | Bukhari I A, Almotrefi A A, Mohamed O Y , et al. Protective effect of fenofibrate against ischemia-/reperfusion-induced cardiac arrhythmias in isolated rat hearts[J]. Fundam Clin Pharmacol, 2018,32(2):141-146. |
| [27] | Lam V H, Zhang L, Huqi A , et al. Activating PPARalpha prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts[J]. Circ Res, 2015,117(1):41-51. |
| [28] | Jaswal J S, Keung W, Wang W , et al. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart[J]. Biochim Biophys Acta, 2011,1813(7):1333-1350. |
| [29] | Yamauchi T, Nio Y, Maki T , et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions[J]. Nature Medicine, 2007,13:332. |
| [30] | Knottnerus S J G, Bleeker J C, Wust R C I , et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle[J]. Rev Endocr Metab Disord, 2018,19(1):93-106. |
| [31] | Mallet R T, Squires J E, Bhatia S , et al. Pyruvate restores contractile function and antioxidant defenses of hydrogen peroxide-challenged myocardium[J]. Journal of Molecular and Cellular Cardiology, 2002,34(9):1173-1184. |
| [32] | Wolff A A, Rotmensch H H, Stanley W C , et al. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective[J]. Heart Failure Reviews, 2002,7(2):187-203. |
| [33] | Ussher J R, Koves T R, Jaswal J S , et al. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking Malonyl CoA Decarboxylase[J]. Diabetes, 2009,58(8):1766-1775. |
| [34] | Mdaki K S, Larsen T D, Wachal A L , et al. Maternal high-fat diet impairs cardiac function in offspring of diabetic pregnancy through metabolic stress and mitochondrial dysfunction[J]. Am J Physiol Heart Circ Physiol, 2016,310(6):H681-H692. |
| [35] | Vlassara H, Uribarri J . Advanced glycation end products (AGE) and diabetes: cause, effect, or both?[J]. Curr Diab Rep, 2014,14(1):453. |
| [36] | Mizushima N, Yoshimori T, Ohsumi Y . The role of Atg proteins in autophagosome formation[J]. Annu Rev Cell Dev Biol, 2011,27:107-132. |
| [37] | Ruiz-Canela M, Toledo E, Clish C B , et al. Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED trial[J]. Clinical Chemistry, 2016,62(4):582-592. |
| [38] | Lu G, Sun H, She P , et al. Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells[J]. J Clin Invest, 2009,119(6):1678-1687. |
| [39] | Newgard C B . Interplay between lipids and branched-chain amino acids in development of insulin resistance[J]. Cell Metab, 2012,15(5):606-614. |
| [40] | Crowe M J, Weatherson J N, Bowden B F . Effects of dietary leucine supplementation on exercise performance[J]. Eur J Appl Physiol, 2006,97(6):664-672. |
| [41] | D'Antona G, Ragni M, Cardile A, et al. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice[J]. Cell Metab, 2010,12(4):362-372. |
| [42] | Li T, Zhang Z, Kolwicz S C, Jr ., et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury[J]. Cell Metab, 2017,25(2):374-385. |
/
| 〈 |
|
〉 |
